Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Narrative Review

Vol. 1 No. 2 (1995)

Elucidating Angiogenesis: The Role of Basement Membrane Proteolysis and Endothelial Cell Motility and Proliferation

  • Neil A. Goldenberg
DOI
https://doi.org/10.26443/mjm.v1i2.725
Submitted
November 9, 2020
Published
2020-12-01

Abstract

N/A

References

  1. Benjamini E, Leskowitz S. Immunology: a short course, 2nd ed. New York: Wiley-Liss, Inc.; 1991
  2. Folkman J, Klagsbrun M. Angiogenic factors. Science 235: 442-447, 1991.
  3. Folkman J. What is the evidence that tumors are angiogenesis dependent? Journal of the National Cancer Institute 82: 4-6; 1990.
  4. Folkman J. Toward an understanding of angiogenesis: search and discovery. Perspectives in Biology and Medicine 29(1): 10-36; 1985.
  5. Koch AE, et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. Journal of Immunology 152(8): 4149-4156; 1994.
  6. Murphy RP. Management of diabetic retinopathy. American Family Physician 51(4): 785-96; 1995.
  7. Ausprunk DH, Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvascular Research 14: 53-65; 1977.
  8. Kleinman HK, et al. The laminins: a family of basement membrane glycoproteins important in cell differentiation and tumor metastases. Vitamins and Hormones 47: 161-184; 1993.
  9. Yanase T, et al. Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Research 53: 2566-2570; 1993.
  10. Gimbrone MA Jr., Cotrans RS, Folkman J. Human vascular endothelial cells in culture: growth and DNA synthesis. Journal of Cell Biology 60: 673-680; 1974.
  11. Ausprunk DH, Knighton DR, Folkman J. Vascularization of normal and neoplastic tissues grafted into the chick chorioallantois. American Journal of Pathology 79: 597-618; 1975.
  12. Passaniti A, et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconsitituted basement membrane, heparin, and fibroblast growth factor. Laboratory Investigation 67: 519-28; 1992.
  13. Gleave ME, et al. Epidermal growth factor receptor-mediated autocrine and paracrine stimulation of human transitional cell carcinoma. Cancer Research 53: 5300-5307; 1993.
  14. Folkman J, et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58-61, 1989.
  15. Browder LW, Erickson CA, Jeffery WR. Developmental Biology, 3rd ed. Philadelphia, PA: Saunders College Publishing; 1991.
  16. Schor SL. Cell proliferation and migration on collagen substrate in vitro. Journal of Cell Science 41: 159-175; 1980.
  17. Delvos U, et al. Interaction of vascular wall cells with collagen gels. Laboratory Investigations 46: 61-72; 1982.
  18. Kalebic T, et al. Basement membrane collagen: degradation by migrating endothelial cells. Science 221: 281-283; 1982.
  19. Folkman J, et al. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 221: 719; 1983.
  20. Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 230: 1375; 1985.
  21. Crum R, Folkman J. Anti-angiogenesis by steroids without glucocorticoid or mineralocorticoid activity in the presence of heparin. Journal of Cell Biology 99: 158a; 1984.
  22. Ingber DE, Madri JA, Folkman J. Anti-angiogenesis by angiostatic steroids in the presence of heparin: induction of basement membrane dissolution. Journal of Cell Biology 101: 105a; 1985.
  23. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336; 1991.
  24. Montesano R, Orci L. Tumor-promoting phorbol esters induce angiogenesis in vitro. Cell 42: 469-477; 1985.
  25. Pepper MS, et al. Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells. Journal of Cell Biology 105: 2535-2541; 1987.
  26. Mignatti P, et al. In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases. Journal of Cell Biology 108: 671-682; 1989.
  27. Pepper MS, et al. Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro. Journal of Cell Biology 111: 743-755; 1990.
  28. Saksela O, Moscatelli D, Rifkin DB. The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells. Journal of Cell Biology 105: 957-963; 1987.
  29. Muller G, et al. Inhibitory action of transforming growth factor beta on endothelial cells. Proceedings of the National Academy of Sciences USA 84: 5600-5604; 1987.
  30. Lin HY, Moustakas A. Cellular and Molecular Biology 40(3): 337-349; 1994.
  31. Weisman DM, et al. Transforming growth factor-beta is chemotactic for human monocytes and induces their expression of angiogenic activity. Biochemical and Biophysical Research Communications 157: 793-800; 1988.
  32. Murphy AN, Unsworth EJ, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinase-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. Journal of Cellular Physiology 157(2): 351-358; 1993.
  33. Schnapper HW, et al. Type IV collagenases and TIMPs modulate endothelial cell morphogenesis in vitro. Journal of Cellular Physiology 156: 235-246; 1993.
  34. Grant DS, et al. Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell 58: 933-943; 1989.
  35. Azizkhan J, et al. Stimulation of increased capillary endothelial cell motility by chondrosarcoma cell-derived factors. Cancer Research 43(7): 3281-3286; 1983.
  36. Bashkin P, et al. Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry 28: 1737-1743; 1989.
  37. Friesel RE, Maciag T. Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB 9(10): 919-925; 1995.
  38. Kim KJ, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844; 1993.
  39. Plate KH, et al. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 359: 845-848; 1992.
  40. Shweiki D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845; 1992.
  41. Connolly DT, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. Journal of Clinical Investigation 84: 1470-1478; 1989.
  42. Favard C, et al. Purification and biological properties of vasculotropin, a new angiogenic cytokine. Biology of the Cell 73(1): 1-6; 1991.
  43. Connolly DT. Vascular permeability factor: a unique regulator of blood vessel function. Journal of Cell Biochemistry 47(3): 219-23; 1991.
  44. Findlay JK. Angiogenesis in reproductive tissues. Journal of Endocrinology 111: 357-366; 1986.
  45. Shweiki D, et al. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. Journal of Clinical Investigation 91(5): 2235-2243; 1993.
  46. Dvorak HF, et al. Vacular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. American Journal of Pathology 146(5): 1029-1039; 1995.
  47. Kavanaugh WM, et al. Transcriptional regulation of the A and B chain genes of platelet-derived growth factor in microvascular endothelial cells. Journal of Biological Chemistry 263: 8470-8472; 1988.
  48. Marx M, Perlmutter RA, Madri JA. Modulation of platelet-derived growth factor receptor expression in microvascular endothelial cells during in vitro angiogenesis. Journal of Clinical Investigation 93(1): 131-139; 1994.
  49. Camussi G, et al. The release of platelet-activating factor from human endothelial cells in culture. Journal of Immunology 131: 2397-2403; 1983.
  50. Camussi G, et al. Platelet-activating factor directly stimulates in vitro migration of endothelial cells and promotes in vivo angiogenesis by a heparin-dependent mechanism. Journal of Immunology 154(12): 6492-6501; 1995.
  51. Zhang Y, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. Journal of Clinical Investigation 94(3): 1320-1327; 1994.
  52. Murray, JC. Coagulation and cancer. British Journal of Cancer 64: 422-424; 1991.
  53. Tolsma S, et al. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. Journal of Cell Biology 122: 497-511; 1993.
  54. Good DJ, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proceedings of the National Academy of Sciences USA 87: 6624-6628; 1990.
  55. Dameron KM, et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582-1584; 1994.
  56. Taraboletti G, et al. Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. Journal of Cell Biology 111: 765-772; 1990.
  57. DiPietro LA, Polverini PJ. Angiogenic macrophages produce the angiogenic inhibitor thrombospondin 1. American Journal of Pathology 143(3): 678-684; 1993.
  58. Azizkhan RG, et al. Mast cell heparin stimulates migration of capillary endothelial cells in vitro. Journal of Experimental Medicine 152(4): 931-944; 1980.
  59. Buonassisi V, Root M. Enzymatic degradation of heparin-related mucopolysaccharides from the surface of endothelial cell cultures. Biochimica et Biophysica Acta 385(1): 1-10; 1975.
  60. Ziche M, et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. Journal of Clinical Investigation 94(5): 2036-2044; 1994.
  61. Ray JM, Stetler-Stevenson WG. The role of matrix metalloproteinases and their inhibitors in tumor invasion, metastasis and angiogenesis. European Respiratory Journal 7: 2062-2072; 1994.
  62. Wolfering EA, et al. Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. Journal of Surgical Research 50: 245-251; 1991.
  63. Patel PC, et al. Postreceptor signal transduction mechanisms involved in octreotide-induced inhibition of angiogenesis. Surgery 116(6): 1148-1152; 1994.
  64. Clapp C, et al. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 133: 1292-1299; 1993.
  65. Polakowski IJ, et al. A ribonuclease inhibitor expresses anti-angiogenic properties and leads to reduced tumor growth in mice. American Journal of Pathology 143(2): 507-517; 1993.
  66. Oreilly MS, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328; 1994.
  67. Sunderköpter C, et al. Macrophage and angiogenesis. Journal of Leukocyte Biology 55: 410-422; 1994.
  68. Sakamoto T, et al. Vessel formation by choroidal endothelial cells in vitro is modulated by retinal pigment epithelial cells. Archives of Ophthalmology 113(4): 512-520; 1995.
  69. Glaser B, et al. Retinal pigment epithelial cells release inhibitors of neovascularization. Ophthalmology 94: 780; 1983.
  70. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine 1(1): 27-31; 1995.
  71. Cozzolino F, et al. Interferon-alpha and interleukin 2 synergistically enhance basic fibroblast growth factor synthesis and induce release, promoting endothelial cell growth. Journal of Clinical Investigation 91(6): 2504-2512; 1993.
  72. Nabel EG, et al. Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo. Nature 362: 844-846; 1993.
  73. Fasol R, et al. Experimental use of a modified fibrin glue to induce site-directed angiogenesis from the aorta to the heart. Journal of Thoracic and Cardiovascular Surgery 107(6): 1432-1439; 1994.
  74. Landau C, Jacobs AK, Haudenschild, CC. Intrapericardial basic fibroblast growth factor induces myocardial angiogenesis in a rabbit model of chronic ischemia. American Heart Journal 129(5): 924-931; 1995.
  75. Ezekowitz RAB, Mulliken JB, Folkman J. Interferon alpha-2a therapy for life-threatening hemangiomas of infancy. New England Journal of Medicine 326: 1456-1463; 1992 (and corrections New England Journal of Medicine 330: 300; 1994).
  76. Cid MC, et al. Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis. Journal of Clinical Investigation 91(3): 977-985; 1993.
  77. Hull MA, Cullen DJE, Hawkey CJ. Basic fibroblast growth factor in gastric ulceration: mucosal levels and therapeutic potential. Gastroenterology 106: A97; 1994.
  78. Wolfe MM, et al. Safety and efficacy of an angiogenic peptide, basic fibroblast growth factor (bFGF) in the treatment of gastroduodenal ulcers: a preliminary report. Gastroenterology 106: A212; 1994.
  79. Vajkoczy P, et al. Histogenesis and ultrastructure of pancreatic islet graft microvasculature. Evidence for graft revascularization by endothelial cells of host origin. American Journal of Pathology 146(6): 1397-1405; 1995.
  80. Kohn E, et al. Phase I trial of signal transduction inhibitor, CAI. Proceedings of the American Association of Cancer Research 35: 244; 1994.
  81. Logan A. Angiogenesis. Lancet 341: 1467-1468; 1993.
  82. Bussolino F, et al. Platelet activating factor produced in vitro by Kaposi's sarcoma cells induces and sustains in vivo angiogenesis. Journal of Clinical Investigation 96(2): 940-952; 1995.
  83. Ensoli B, et al. Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS. Journal of Clinical Investigation 94(5): 1736-1746; 1994.
  84. Hollingsworth HC, et al. Tumor angiogenesis in advanced stage ovarian carcinoma. American Journal of Pathology 147(1): 33-41; 1995.

Downloads

Download data is not yet available.

Similar Articles

You may also start an advanced similarity search for this article.